Corticosteroids for ocular toxoplasmosis

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Vedula, Satyanarayana S ^b   Nguyen, Quan D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARASITIC AGENT; CORTICOSTEROID;

ADJUVANT THERAPY; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DRUG EFFECT; DRUG USE; EYE DISCOMFORT; HUMAN; INFORMATION PROCESSING; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TOXOPLASMOSIS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 55049123467     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007417     Document Type: Review

References (14)

1. Anderson 1979 Anderson S. Toxoplasma gondii. In: Mandell Gl, Douglas RG Jr, Bennet JE editor(s). Principles and practice of infectious diseases. New York: John Wiley & Sons, 1979.
2. Bloch-Michel 1987 Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. American Journal of Ophthalmology 1987;103(2):234-5.
3. Fine 1981 Fine SL, Owens SL, Haller JA, Knox DL, Patz A. Choroidal neovascularization as a late complication of ocular toxoplasmosis. American Journal of Ophthalmology 1981;91(3):318-22.
4. Folk 1984 Folk JC, Lobers LA. Presumed toxoplasmis papillitis. Ophthalmology 1984;91(1):64-7.
5. Gilbert 1999 Gilbert RE, Dunn DT, Lightman S, Murray PI, Pavesio CE, Gormley PD, et al.Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiology and Infection 1999;123 (2):283-9.
6. Gilbert 2002 Gilbert RE, Harden M, Stanford MR. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database of Systematic Reviews 2002, Issue 1. [Art. No.: CD002218. DOI: 10.1002/14651858.CD002218]
7. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
8. Higgins 2008a Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
9. Higgins 2008b Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook. org.
10. Hogan 1959 Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis. I. Anterior uveitis. American Journal of Ophthalmology 1959;47(5, part 2):155-70.
11. Klaren 2002 Klaren VN, Kijlstra A. Toxoplasmosis, an overview with emphasis on ocular involvement. Ocular Immunology & Inflammation 2002; 10(1):1-26.
12. Lum 2005 Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. American Journal of Ophthalmology 2005;140(4):724-7.
13. Nussenblatt 1985 Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92(4):467-71.
14. Parmar 1998 Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform metaanalyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.